Certara (NASDAQ:CERT) Price Target Lowered to $9.00 at Stephens

Certara (NASDAQ:CERT) had its price objective reduced by equities researchers at Stephens from $10.00 to $9.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Stephens’ price target indicates a potential upside of 79.28% from the company’s previous close.

CERT has been the subject of a number of other research reports. Wall Street Zen cut shares of Certara from a “buy” rating to a “hold” rating in a research report on Sunday, February 15th. TD Cowen reaffirmed a “buy” rating on shares of Certara in a research note on Thursday, February 26th. Morgan Stanley cut their target price on shares of Certara from $11.00 to $10.00 and set an “equal weight” rating for the company in a research note on Tuesday. Craig Hallum downgraded Certara from a “buy” rating to a “hold” rating and set a $10.00 target price on the stock. in a report on Friday, February 27th. Finally, Barclays dropped their price target on Certara from $8.00 to $6.50 and set an “equal weight” rating for the company in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $9.35.

Certara Trading Down 2.1%

Shares of CERT opened at $5.02 on Tuesday. The company has a current ratio of 2.05, a quick ratio of 2.05 and a debt-to-equity ratio of 0.27. The stock has a market cap of $769.67 million, a PE ratio of -501.50 and a beta of 1.53. Certara has a 1 year low of $4.99 and a 1 year high of $13.88. The stock has a 50 day simple moving average of $6.21 and a 200-day simple moving average of $8.01.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Monday, May 11th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.11 by ($0.02). The company had revenue of $106.92 million during the quarter, compared to analyst estimates of $106.13 million. Certara had a negative net margin of 0.38% and a positive return on equity of 4.20%. Certara’s quarterly revenue was up .8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.14 EPS. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. On average, sell-side analysts predict that Certara will post 0.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Tejara Capital Ltd increased its stake in shares of Certara by 94.9% in the 3rd quarter. Tejara Capital Ltd now owns 273,052 shares of the company’s stock valued at $3,337,000 after buying an additional 132,927 shares during the period. Fort Washington Investment Advisors Inc. OH boosted its holdings in Certara by 133.4% in the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 2,272,823 shares of the company’s stock valued at $20,024,000 after acquiring an additional 1,299,109 shares during the last quarter. Dixon Mitchell Investment Counsel Inc. acquired a new stake in Certara in the third quarter worth about $10,587,000. Sector Gamma AS acquired a new stake in Certara in the third quarter worth about $2,818,000. Finally, Kopion Asset Management LLC raised its holdings in Certara by 49.9% during the 4th quarter. Kopion Asset Management LLC now owns 982,710 shares of the company’s stock worth $8,658,000 after purchasing an additional 327,064 shares during the last quarter. Institutional investors own 73.96% of the company’s stock.

Certara News Summary

Here are the key news stories impacting Certara this week:

• Negative Sentiment: Certara reported Q1 2026 EPS of $0.09, below the $0.11 consensus, even though revenue came in slightly ahead of expectations. Certara Q1 2026 earnings report
• Negative Sentiment: The company lowered FY 2026 guidance to EPS of $0.35-$0.41 and revenue of $395 million-$405 million, both below Wall Street expectations, which is weighing on sentiment. Certara guidance update
• Negative Sentiment: After the earnings release, Certara hit a new 52-week low and trading was briefly halted for an LULD pause, reflecting heightened volatility and bearish reaction. Certara new 52-week low article
• Negative Sentiment: Morgan Stanley cut its price target on Certara to $10 from $11 and kept an equal-weight rating, signaling more cautious expectations despite implied upside from current levels. Morgan Stanley price target cut
• Negative Sentiment: Robert W. Baird also lowered its target to $6 from $7 and maintained a neutral rating, adding to the cautious analyst tone. Robert W. Baird price target cut
• Neutral Sentiment: Management said AI investments should support long-term growth, but traders are currently prioritizing the near-term warning tied to guidance. MSN article on AI investments

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.